Inspira Technologies (IINN) Listed FDA Class I 510(k) Exempt component of the ART system

Inspira Technologies OXY B.H.N. Ltd. (NASDAQ: IINN) (NASDAQ: IINNW), a groundbreaking respiratory support technology company, announced today that has listed a component of its ART and ECLS systems on the U.S. Food and Drug Administration Class I 510(k) exempt list.

The component is intended to reduce the potential complications associated with jugular vein cannula movement, occurring during a change of a patient's posture in bed and/or during transportation. The component can also be potentially utilized in the treatment of thousands of patients being treated each year by Extracorporeal Membrane Oxygenation (ECMO). This component is expected to allow the medical staff a safer mobilization for the awake cannulated patients within and between hospitals and medical centers.

You May Also Be Interested In

• AstraZeneca (AZN) Announces Voydeya Approval in EU as add-on to ravulizumab or eculizumab
• Legend Biotech (LEGN) Reports CARVYKTI Approved in EU
• Guardant Health (GH) Announces FDA Advisory Panel Review of Shield Blood Test to Screen for Colorectal Cancer to Be Held on May 23